<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="819">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <nctid>NCT00191698</nctid>
  <trial_identification>
    <studytitle>Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD</studytitle>
    <scientifictitle>A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride and Placebo in Child and Adolescent Outpatients With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>B4Z-MC-LYBX</secondaryid>
    <secondaryid>7068</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Attention Deficit Hyperactivity Disorder</healthcondition>
    <healthcondition>Oppositional Defiant Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - atomoxetine hydrochloride
Treatment: drugs - placebo

Experimental: A - Atomoxetine is administered at 1.2 mg/kg/day, PO for 8 weeks, followed by 1.2 or 2.4 mg/kg/day, PO for 4 weeks, open label administration can continue for up to one year

Placebo Comparator: B - Placebo is administered by mouth, daily for 8 weeks. After 8 weeks, those randomized to placebo may be titrated to 1.2 mg/kg/day atomoxetine for the remainder of the study up to one year


Treatment: drugs: atomoxetine hydrochloride


Treatment: drugs: placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean reduction in ODD symptoms using the Swanson, Nolan and Pelham Rating Scale-Revised (SNAP-IV), atomoxetine vs placebo</outcome>
      <timepoint>over 8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in the investigator-rated SNAP-IV ADHD subscales, atomoxetine vs placebo</outcome>
      <timepoint>over 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in ratings on the Oppositional subscale of the SNAP-IV</outcome>
      <timepoint>over 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in ADHD symptoms by ADHD subscales of the SNAP-IV, 2.4 mg/kg/day vs 1.2 mg/kg/day.</outcome>
      <timepoint>over 4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in ratings on the Clinical Global Impressions-Severity (CGI-S).</outcome>
      <timepoint>over 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Psychosocial functioning as measured by the total score on the Attention Deficit Hyperactivity Disorder Impact Module (AIM).</outcome>
      <timepoint>over 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Environmental stress exacerbation of ODD symptoms by Social Readjustment Rating Scale (SRRS).</outcome>
      <timepoint>8 weeks, 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events (AEs)</outcome>
      <timepoint>over 1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients are male or female outpatients who are at least 6 years of age and not more
             than 12 years of age at study entry.

          -  Patients must meet DSM-IV diagnostic criteria for ADHD and ODD.

          -  If other comorbid conditions are present, either the ADHD or the ODD diagnosis must be
             the patient's primary diagnosis.

          -  Patients must have laboratory results, including serum chemistries, hematology, and
             urinalysis showing no significant abnormalities.

          -  Patients must have an ECG performed at study entry that is absent of any abnormality
             that, in the opinion of the physician, should exclude the patient.</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Patients who weigh less than 20 kg or greater than 60 kg at study entry.

          -  Patients who have a history of Bipolar I or II disorder, psychosis, or pervasive
             developmental disorder.

          -  Patients who have a current diagnosis of Major Depressive Disorder ([MDD]; with or
             without psychotic features), PTSD, or CDRS-R total raw score &gt;40 at study entry.

          -  Patients with a history of any seizure disorder.

          -  Patients determined by the investigator to be at serious suicidal risk.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>226</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Wallsend</hospital>
    <hospital>For additional information regarding investigative sites for this trial, call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Parkville</hospital>
    <postcode>2287 - Wallsend</postcode>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Risskov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Augus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to test the effectiveness of atomoxetine in treating symptoms of
      ODD in children with ADHD and ODD.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00191698</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>